Log in to save to my catalogue

Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe dise...

Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe dise...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5096052

Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Immunogenicity of recombinant human acid-alpha glucosidase (rhGAA) in enzyme replacement therapy (ERT) is a safety and efficacy concern in the management of late-onset Pompe disease (LOPD). However, long-term effects of ERT on humoral and cellular responses to rhGAA are still poorly understood. To better understand the impact of immunogenicity of r...

Alternative Titles

Full title

Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5096052

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5096052

Other Identifiers

ISSN

2045-2322

E-ISSN

2045-2322

DOI

10.1038/srep36182

How to access this item